Cargando…
Etanercept in axial spondyloarthritis
Autores principales: | Luo, Gui, Zhu, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945552/ https://www.ncbi.nlm.nih.gov/pubmed/35261349 http://dx.doi.org/10.1097/CM9.0000000000001986 |
Ejemplares similares
-
Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019) -
The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2021) -
Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
por: Li, Kun-Peng, et al.
Publicado: (2018) -
Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update"
por: Braun, Juergen
Publicado: (2023) -
Axial spondyloarthritis: synthetic magnetic resonance imaging in the detection of sacroiliac joint lesions
por: Zhang, Ke, et al.
Publicado: (2022)